As a dual partial PPAR α/δ agonist, C15:0 has a targeted mechanism of action proposed to treat NAFLD and NASH, and as shown in our current study, C15:0 has direct, dose-dependent, and clinically relevant beneficial activities across multiple primary human cell systems relevant to NASH, including anti-inflammatory and antifibrotic activities; similar benefits have been reported in hepatic cells [2,27,87]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.